Radar on Specialty Pharmacy

CVS-CTCA Pilot Offers In-Home Infusion of Cancer Therapies

As the U.S. surpasses 500,000 deaths from the COVID-19 pandemic, people with cancer continue to unsurprisingly be hesitant to visit a provider office or hospital for treatment. So, Cancer Treatment Centers of Americ...
0 Comments
© 2024 MMIT

New Long-Acting HIV Regimen May Help Patient Adherence

The FDA recently approved the first long-acting regimen for the treatment of HIV in adults. The dosing schedule could help with adherence in a condition where that is particularly crucial. However, some potential ch...
0 Comments
© 2024 MMIT

Evolution of Medicine Has Produced Novel New Treatments

Therapeutic interventions have evolved from people taking a pill every day to treat a condition to the one-time cell and gene therapies aimed at halting disease progression or even curing a disease. The rise of thes...
0 Comments
© 2024 MMIT

New FDA Specialty Approvals

✦ Feb. 3: The FDA gave accelerated approval to Merck KGaA unit EMD Serono, Inc.’s Tepmetko (tepotinib) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithel...
0 Comments
© 2024 MMIT

News Briefs

✦ AstraZeneca said Feb. 22 that it would voluntarily withdraw the Imfinzi (durvalumab) indication in the U.S. for previously treated adults with locally advanced or metastatic urothelial carcinoma who have disease...
0 Comments
© 2024 MMIT

2021 Outlook: Gene, Orphan, CAR-T Therapies Are in Pipeline Spotlight

The pharmaceutical industry has undergone an unprecedented burst of innovation lately, led — but by no means limited to — the race to develop a vaccine to counter the COVID-19 pandemic, and this trend is showing...
0 Comments
© 2024 MMIT

Orgovyx Offers New Oral Option for People With Prostate Cancer

People being treated for advanced prostate cancer now have a new oral option, offering patients the ability to not have to visit a provider for administration — an especially welcome alternative during the COVID-1...
0 Comments
© 2024 MMIT

2021 Outlook: With 20 Biosimilars Available, U.S. Market Is Heating Up

As of the beginning of February, the FDA had approved 29 biosimilars. For various reasons, mostly patent litigation by reference drug companies, only 20 of those products actually have launched onto the U.S. market....
0 Comments
© 2024 MMIT

Shields’ Purchase of Excelera Will Help With Payer Contracts

As more health systems are creating their own specialty pharmacies, two major players in the space are coming together. In mid-January, Shields Health Solutions unveiled a deal to purchase ExceleraRx Corp. for an un...
0 Comments
© 2024 MMIT

Specialty Pharmacy, Infusion M&A Activity Is Slowing Down

The level of merger and acquisition (M&A) activity within the specialty pharmacy and home infusion arenas that has been occurring for numerous years has certainly depleted the number of companies available for d...
0 Comments
© 2024 MMIT